Rheumatology – Page 2

Therapeutic Strategies for Disease-Modifying Therapy Management in Pregnant Women With Multiple Sclerosis: Relapse Risk and Clinical Implications

By MedXY 08/04/2025

Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.

Allergy & Immunology Medical News news Rheumatology Specialties

Fine Particulate Matter Exposure Significantly Increases SLE Risk

By MedXY 08/04/2025

A large Taiwanese cohort study links higher PM2.5 exposure to a more than threefold increased risk of developing systemic lupus erythematosus, underscoring the need for air quality policy interventions.

Clinical Updates news Rheumatology Specialties

Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy

By MedXY 08/03/2025

A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

By MedXY 08/03/2025

A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.

Clinical Updates news Radiology Rheumatology Specialties

Functional MRI Brain Activation as a Predictor of Response to TNF Inhibition in Rheumatoid Arthritis: Insights from the PreCePra Phase 3 Study

By MedXY 08/02/2025

A phase 3 trial indicates that fMRI-detected CNS pain activation may predict which rheumatoid arthritis patients respond best to TNF inhibitor therapy.

Clinical Updates news Rheumatology Specialties

Sarilumab in Relapsing Polymyalgia Rheumatica: Clinical Efficacy and Patient-Reported Outcomes from Recent Phase 3 Trials

By MedXY 08/02/2025

Sarilumab demonstrates significant improvement in disease control and quality of life for patients with relapsing polymyalgia rheumatica, enabling glucocorticoid sparing and sustained remission.

Clinical Updates Medical News Rheumatology Specialties

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

By MedXY 08/02/2025

Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.

$FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease$

Clinical Updates news Rheumatology Specialties

FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease

By MedXY 07/31/2025

The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.

Clinical Updates news Rheumatology Specialties

Polymyalgia Rheumatica Not Associated with Increased Mortality: Insights from a 38-Year Norwegian Cohort Study

By MedXY 07/31/2025

A 38-year prospective study in Southern Norway demonstrates that isolated polymyalgia rheumatica (PMR) does not increase all-cause mortality compared to matched population controls, with men showing even lower mortality risk.

Clinical Updates news Rheumatology Specialties

Rituximab Shows No Superiority Over Conventional Therapy for EGPA Remission Induction

By MedXY 07/31/2025

A phase 3 randomized trial found rituximab no more effective than standard glucocorticoid-based therapy in inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), with comparable safety and relapse profiles.

Clinical Updates news Rheumatology Specialties

Low Lupus Activity as a Predictive Target in Lupus Nephritis: A Clinical Appraisal of LLDAS

By MedXY 07/30/2025

Achieving low lupus disease activity (LLDAS) at 12 months is an attainable target in lupus nephritis and independently predicts reduced relapse risk and preserved renal function, supporting its potential as a future treatment goal.

Medical News Rheumatology Specialties

Johns Hopkins Hospital Leads U.S. News Rheumatology Rankings

By Dr.Paul 07/30/2025

Highlight Johns Hopkins Hospital is ranked as the best hospital for rheumatology for the 8th…

Clinical Updates news Rheumatology Specialties

Personal and Household Pesticide Exposure Linked to Increased Risk of Rheumatoid Arthritis in Female Farm Spouses

By MedXY 07/30/2025

New evidence links direct and indirect exposure to specific agricultural pesticides with increased risk of incident rheumatoid arthritis among female spouses of licensed pesticide applicators.

news Rheumatology Specialties

WHO Releases Comprehensive Guidelines for Managing Sickle Cell Disease in Pregnancy

By MedXY 07/28/2025

New WHO guidelines offer evidence-based approaches to improve care for pregnant women with sickle cell disease, focusing on treatment and maternal outcomes.